The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Semi-Solid Dosage Contract Manufacturing Market Over The Period 2026–2030?
The semi-solid dosage contract manufacturing market has experienced rapid expansion in recent years. It is projected to increase from $17.97 billion in 2025 to $19.89 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. This growth observed in the historical period is attributable to an increasingly complex pharmaceutical pipeline, rising cost pressures on internal manufacturing, the wider adoption of topical and transdermal drugs, an escalating demand for contract manufacturing services, and the accessibility of specialized cmo capabilities.
The semi-solid dosage contract manufacturing market size is projected to experience swift expansion over the coming years. By 2030, it is anticipated to reach $29.52 billion, expanding at a compound annual growth rate (CAGR) of 10.4%. During the forecast period, this growth can be ascribed to several factors, including a heightened demand for personalized topical therapies, increased investments in advanced formulation technologies, the broadening of cosmeceutical outsourcing, an amplified focus on sustainable excipient usage, and greater regulatory oversight concerning manufacturing quality. Key trends for the forecast period encompass a surge in the outsourcing of semi-solid drug manufacturing, an escalating demand for specialized dermatological formulations, the increasing implementation of flexible manufacturing lines, the growth of bio-based and natural formulations, and a strengthened emphasis on production that complies with regulations.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25899&type=smp
What Underlying Factors Are Accelerating The Growth Of The Semi-Solid Dosage Contract Manufacturing Market?
The increasing occurrence of skin conditions is projected to drive expansion within the semi-solid dosage contract manufacturing market in the future. Skin ailments are defined as conditions impacting the skin’s look or operation, frequently presenting symptoms like discomfort, redness, or unusual dermal formations. The surge in skin disorders is attributable to escalating environmental contamination, which compromises the skin’s protective barriers, resulting in heightened sensitivity, allergic responses, and ongoing dermatological issues. Through the provision of dependable, high-quality topical solutions that effectively preserve and enhance dermal well-being, the contract manufacturing of semi-solid dosage forms aids in preventing skin diseases. As an illustration, data from Cancer Research UK, a UK-based cancer research organization, indicated in February 2023 that the average annual occurrence of melanoma skin cancer in the UK is forecast to increase from approximately 20,800 cases between 2023–2025 to nearly 26,500 cases by the period 2038–2040. Consequently, the widespread occurrence of skin conditions is propelling the growth of the semi-solid dosage contract manufacturing market.
How Is The Semi-Solid Dosage Contract Manufacturing Market Divided Into Its Major Segments?
The semi-solid dosage contract manufacturing market covered in this report is segmented –
1) By Type: Topical, Transdermal, Oral
2) By Material Type: Synthetic, Natural, Bio-Based
3) By Company Size: Large Size Companies, Medium And Small Size Companies
4) By Therapeutic Application: Dermatology, Pain Management, Hormonal Therapy, Wound Care, Ophthalmic Disorders, Other Therapeutic Applications
5) By End Use: Pharmaceutical Companies, Cosmeceutical Companies, Other End Uses
Subsegments:
1) By Topical: Creams, Ointments, Gels, Lotions, Pastes, Foams
2) By Transdermal: Transdermal Gels, Transdermal Creams, Transdermal Sprays, Transdermal Emulsions, Medicated Patches
3) By Oral: Oral Gels, Oral Pastes, Oral Suspensions, Oral Emulsions, Oral Jellies
Which Trends Are Influencing The Semi-Solid Dosage Contract Manufacturing Market?
Leading companies active in the semi-solid dosage contract manufacturing market are focusing on strategic investments to access new markets and foster innovation. Strategic investments are long-term financial decisions designed to uphold and strengthen a company’s primary objectives, future growth, or its competitive position in the market. As an illustration, in March 2025, LGM Pharma, a US-based provider of semi-solid dosage contract manufacturing services, announced an investment exceeding $6 million dedicated to enlarging its manufacturing facility in Rosenberg, Texas. This investment aims to significantly increase production capacity for liquid, suspension, semi-solid, and suppository drug formulations to meet the rising demand for domestic pharmaceutical manufacturing. It aligns with LGM Pharma’s ongoing expansion in prescription drug development, including 505(b)(2) and ANDA programs. The upgrades at the Rosenberg site are set to support higher output while ensuring complete compliance with FDA requirements and current good manufacturing practices. The facility is expected to continue its operations without interruption during the expansion process.
Who Are The Prominent Organizations Shaping The Semi-Solid Dosage Contract Manufacturing Market?
Major companies operating in the semi-solid dosage contract manufacturing market are The Lubrizol Corporation, Recipharm AB, Piramal Pharma Solutions Inc., Cambrex Corporation, ANI Pharmaceuticals, Aurigene Pharmaceutical Services Limited, DPT Laboratories Ltd., Douglas Pharmaceuticals Ltd., Mission Pharmacal Co., Bora Pharmaceuticals Co. Ltd., Ascendia Pharmaceuticals Inc., Fermion Oy, Ferndale Pharma Group, Sterling Pharmaceutical Services LLC, Aphena Pharma Solutions Inc., Eubioco LLC, Madras Pharmaceuticals, Quality CDMO, Axxelent Pharma Science, Tergus Pharma, MedPharm Ltd., Alcami Corporation
Read the full semi-solid dosage contract manufacturing market report here:
Which Region Is Projected To Dominate The Semi-Solid Dosage Contract Manufacturing Market During The Forecast Period?
North America was the largest region in the semi-solid dosage contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the semi-solid dosage contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Semi-Solid Dosage Contract Manufacturing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25899&type=smp
Browse Through More Reports Similar to the Global Semi-Solid Dosage Contract Manufacturing Market 2026, By The Business Research Company
Oral Solid Dosage Pharmaceutical Formulation Global Market Report
Fill Finish Pharmaceutical Contract Manufacturing Global Market Report
Pharmaceutical Continuous Manufacturing Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model